Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhou, Weiqiang ^a   Feng, Xiuyan ^a   Han, Han ^a   Guo, Shanchun ^b   Wang, Guangdi ^b  

^a SHENYANG MEDICAL COLLEGE   (China)

^b XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VORINOSTAT;

BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; MCF-7 CELL LINE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; RECEPTORS, GROWTH FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84974733607     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28004     Document Type: Article

References (72)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics. CA Cancer J Clin 65, 5-29, doi: 10.3322/caac.21254 (2015).
2. Lim, E., Metzger-Filho, O. & Winer, E. P. The natural history of hormone receptor-positive breast cancer. Oncology 26, 688-694, 696, doi: 168409 (2012).
3. Huang, B., Warner, M. & Gustafsson, J. A. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol 26, 00371-00372, doi: S0303-7207(14)00371-2 (2014).
4. van, d. V. S., Smit, V. T., Dekker, T. J., Nortier, J. W. & Kroep, J. R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev 37, 422-430, doi: S0305-7372(10)00207-0 (2011).
5. Barni, S., Cabiddu, M. & Petrelli, F. Benefit of adjuvant chemotherapy in elderly ER-negative breast cancer patients: Benefits and pitfalls. Expert Rev Anticancer Ther 10, 185-198, doi: 10.1586/era.09.188 (2010).
6. Zhao, M. & Ramaswamy, B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol 5, 248-262, doi: 10.5306/wjco.v5.i3.248 (2014).
7. Kerdivel, G., Flouriot, G. & Pakdel, F. Modulation of estrogen receptor alpha activity and expression during breast cancer progression. Vitam Horm 93, 135-160, doi: B978-0-12-416673-8.00004-6 (2013).
8. Stone, A. et al. Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. Plos one 7, e40466, doi: 10.1371/journal.pone.0040466 (2012).
9. Yang, X. et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 60, 6890-6894 (2000).
10. Kawai, H., Li, H., Avraham, S., Jiang, S. & Avraham, H. K. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107, 353-358, doi: 10.1002/ijc.11403 (2003).
11. Jang, E. R. et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. Oncogene 23, 1724-1736, doi: 10.1038/sj.onc.1207315 (2004).
12. Sharma, D. et al. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol 19, 1740-1751, doi: Me.2004-0011 (2005).
13. Marks, P. A. Discovery and development of SAHA as an anticancer agent. Oncogene 26, 1351-1356, doi: 1210204 (2007).
14. Richon, V. M., Garcia-Vargas, J. & Hardwick, J. S. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 280, 201-210, doi: S0304-3835(09)00002-0 (2009).
15. Chiu, H. W. et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. Plos one 8, e76340, doi: 10.1371/journal.pone.0076340 (2013).
16. Bellarosa, D. et al. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol 41, 1486-1494, doi: 10.3892/ijo.2012.1551 (2012).
17. Shankar, S. et al. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 8, 1596-1605, doi: 1535-7163.MCT-08-1004 (2009).
18. Munster, P. N. et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61, 8492-8497 (2001).
19. Huang, L. & Pardee, A. B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 6, 849-866 (2000).
20. Glaser, K. B. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol 74, 659-671, doi: S0006-2952(07)00226-2 (2007).
21. Gryder, B. E., Sodji, Q. H. & Oyelere, A. K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4, 505-524, doi: 10.4155/fmc.12.3 (2012).
22. Lim, B. et al. Targeting TRAIL in the treatment of cancer: New developments. Expert Opin Ther Targets 25, 1-15, doi: 10.1517/14728222.2015.1049838 (2015).
23. Alexiou, G. A., Tsamis, K. I. & Kyritsis, A. P. Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas. Semin Pediatr Neurol 22, 35-39, doi: S1071-9091(14)00090-4 (2015).
24. Trivedi, R. & Mishra, D. P. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol 5, 69, doi: 10.3389/fonc.2015.00069 (2015).
25. Fulda, S. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Adv Exp Med Biol 818, 167-180, doi: 10.1007/978-1-4471-6458-6-8 (2014).
26. Pan, G. et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277, 815-818 (1997).
27. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821 (1997).
28. Merino, D., Lalaoui, N., Morizot, A., Solary, E. & Micheau, O. TRAIL in cancer therapy: Present and future challenges. Expert Opin Ther Targets 11, 1299-1314, doi: 10.1517/14728222.11.10.1299 (2007).
29. Nagane, M., Huang, H. J. & Cavenee, W. K. The potential of TRAIL for cancer chemotherapy. Apoptosis 6, 191-197 (2001).
30. Emery, J. G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273, 14363-14367 (1998).
31. Fili, S., Karalaki, M. & Schaller, B. Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett 283, 10-19, doi: S0304-3835(09)00026-3 (2009).
32. Baetu, T. M. & Hiscott, J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13, 199-207 (2002).
33. Dai, X. et al. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med 240, 760-773, doi: 1535370215579167 (2015).
34. Pavet, V. et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 70, 1101-1110, doi: 0008-5472.CAN-09-2889 (2010).
35. Soria, J. C. et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 28, 1527-1533, doi: JCO.2009.25.4847 (2010).
36. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 8, 132-140 (2008).
37. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11, 71-76, doi: Nm1160 (2005).
38. Wu, X. et al. Up-regulation of P21 inhibits TRAIL-mediated extrinsic apoptosis, contributing resistance to SAHA in acute myeloid leukemia cells. Cell Physiol Biochem 34, 506-518, doi: 000363018 (2014).
39. Chopin, V., Slomianny, C., Hondermarck, H. & Le, B. X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res 298, 560-573, doi: 10.1016/j.yexcr.2004.04.038 (2004).
40. Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609-4623, doi: 1208585 (2005).
41. Butler, L. M. et al. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 119, 944-954, doi: 10.1002/ijc.21939 (2006).
42. Liu, G. G., Fong, E. & Zeng, X. GNCPro: Navigate human genes and relationships through net-walking. Adv Exp Med Biol 680, 253-259, doi: 10.1007/978-1-4419-5913-3-29 (2010).
43. Roshan, M. M. et al. Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology 67, 379-386, doi: 10.1007/s10616-014-9692-5 (2015).
44. Scrace, S., O'Neill, E., Hammond, E. M. & Pires, I. M. Use of the xCELLigence system for real-time analysis of changes in cellular motility and adhesion in physiological conditions. Methods Mol Biol 1046, 295-306, doi: 10.1007/978-1-62703-538-5-17 (2013).
45. Atienzar, F. A., Gerets, H., Tilmant, K., Toussaint, G. & Dhalluin, S. Evaluation of impedance-based label-free technology as a tool for pharmacology and toxicology investigations. Biosensors 3, 132-156, doi: 10.3390/bios3010132 (2013).
46. Hodges-Gallagher, L., Valentine, C. D., Bader, S. E. & Kushner, P. J. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105, 297-309, doi: 10.1007/s10549-006-9459-6 (2007).
47. Min, A. et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res 17, 33, doi: 10.1186/s13058-015-0534-y (2015).
48. Carlisi, D. et al. The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells. J Cell Physiol 230, 1276-1289, doi: 10.1002/jcp.24863 (2015).
49. Rahman, M. et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113, 217-230, doi: 10.1007/s10549-008-9924-5 (2009).
50. Park, C. et al. Beta-sitosterol sensitizes MDA-MB-231 cells to TRAIL-induced apoptosis. Acta Pharmacol Sin 29, 341-348, doi: 10.1111/j.1745-7254.2008.00761.x (2008).
51. Lauricella, M., Ciraolo, A., Carlisi, D., Vento, R. & Tesoriere, G. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie 94, 287-299, doi: S0300-9084(11)00228-8 (2012).
52. Paoli, P., Giannoni, E. & Chiarugi, P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta 1833, 3481-3498, doi: S0167-4889(13)00249-8 (2013).
53. Simpson, C. D., Anyiwe, K. & Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett 272, 177-185, doi: S0304-3835(08)00394-7 (2008).
54. Gillenwater, A. M., Zhong, M. & Lotan, R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6, 2967-2975, doi: 6/11/2967 (2007).
55. Fandy, T. E., Shankar, S., Ross, D. D., Sausville, E. & Srivastava, R. K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 7, 646-657 (2005).
56. Shankar, S. et al. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: Involvement of both death receptor and mitochondrial pathways. Int J Mol Med 16, 1125-1138 (2005).
57. Facchetti, F. et al. Modulation of pro-and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9, 573-582, doi: 10.1023/B:APPT.0000038036.31271.50 (2004).
58. Oltvai, Z. N., Milliman, C. L. & Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74, 609-619, doi: 0092-8674(93)90509-O (1993).
59. Walensky, L. D. & Gavathiotis, E. BAX unleashed: The biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 36, 642-652, doi: S0968-0004(11)00142-3 (2011).
60. Domingo-Domenech, J. et al. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 112, 53-62, doi: 10.1007/s10549-007-9837-8 (2008).
61. Feng, J. et al. Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer. Cancer Biol Ther 11, 477-489, doi: 14529 (2011).
62. Kamradt, M. C. et al. The small heat shock protein alpha B-crystallin is a novel inhibitor of TRAIL-induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280, 11059-11066, doi: M413382200 (2005).
63. Singh, T. R., Shankar, S., Chen, X., Asim, M. & Srivastava, R. K. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63, 5390-5400 (2003).
64. Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K. & Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59, 734-741 (1999).
65. Janicke, R. U., Sprengart, M. L., Wati, M. R. & Porter, A. G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273, 9357-9360 (1998).
66. Huang, L., Sowa, Y., Sakai, T. & Pardee, A. B. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites. Oncogene 19, 5712-5719, doi: 10.1038/sj. onc.1203963 (2000).
67. Xu, S. Q. & El-Deiry, W. S. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 269, 179-190, doi: 10.1006/bbrc.2000.2247 (2000).
68. Qi, X. W. et al. High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. Oncol Rep 28, 1231-1236, doi: 10.3892/or.2012.1906 (2012).
69. van, A. T. et al. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 17, 215-230, doi: ERC-09-0062 (2010).
70. Milde-Langosch, K., Kappes, H., Riethdorf, S., Loning, T. & Bamberger, A. M. FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat 77, 265-275 (2003).
71. O'Connor, K. & Chen, M. Dynamic functions of RhoA in tumor cell migration and invasion. Small GTPases 4, 141-147, doi: 25131 (2013).
72. Ma, L. et al. Over expression of RhoA is associated with progression in invasive breast duct carcinoma. Breast J 16, 105-107, doi: TBJ860 (2010).